SPPI News and Press, Spectrum Pharmaceuticals Inc. From 02/28/19

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2018 Results Earnings Conference Call February 28, 2019, 04:30 PM ET Company Participants Shiv Kapoor - Vice President of Strategic Planning and Investor Relations Kurt Gustafson - Executive Vice President, Chief Financial Officer and Princi...

Spectrum Pharmaceuticals (NASDAQ: SPPI ): Q4 Non-GAAP EPS of -$0.30 misses by $0.01 ; GAAP EPS of -$0.47 misses by $0.18 . Revenue of $29.4M (+2.8% Y/Y) beats by $4.35M . Press Release More news on: Spectrum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks ne...

Poziotinib enrollment completed in previously treated EGFR cohort (cohort 1) of ZENITH20 trial; topline results are expected in Q4 2019 ROLONTIS ® (eflapegrastim) Biologics License Application (BLA) was submitted to the FDA Q4 Revenues were $29.4 million, including $28.0 mill...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) is scheduled to announce Q4 earnings results on Thursday, February 28th, after market close. More news on: Spectrum Pharmaceuticals, Inc., Earnings news and commentary, , Healthcare stocks news, Read more ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, February 28, 2019 at...

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York. The company presentation is on Thursday, February ...

One, which I mention several times elsewhere, is the need for patience if big profits are to be made from investment. Put another way, it is often easier to tell what will happen to the price of a stock than how much time will elapse before it happens. The other is the inherently deceptive na...

Results are expected in the second half of 2019 Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced full enrollment of cohort 1 (...

Image source: Vectorstock If you want to have a better performance than the crowd, you must do things differently from the crowd. - Sir John Templeton For three months leading to Christmas 2018, the stock market witnessed an overall strong negative sentiment. Most investors were high...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) submits a biologics license application with the U.S. Food and Drug Administration for Rolontis eflapegrastim, a potential treatment for low white blood cell levels caused by a certain type of chemotherapy breast cancer patients. More news on: Spe...